These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33098265)

  • 1. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
    Teo MY; Seier K; Ostrovnaya I; Regazzi AM; Kania BE; Moran MM; Cipolla CK; Bluth MJ; Chaim J; Al-Ahmadie H; Snyder A; Carlo MI; Solit DB; Berger MF; Funt S; Wolchok JD; Iyer G; Bajorin DF; Callahan MK; Rosenberg JE
    J Clin Oncol; 2018 Jun; 36(17):1685-1694. PubMed ID: 29489427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
    J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
    Yin M; Grivas P; Wang QE; Mortazavi A; Emamekhoo H; Holder SL; Drabick JJ; Woo MS; Pal S; Vasekar M; Folefac E; Clinton SK; Monk P; Joshi M
    Oncologist; 2020 Aug; 25(8):680-688. PubMed ID: 32275806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
    Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
    BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
    Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
    Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials.
    Li F; Wang Y; Xie K; Fang Y; Du Y; Hou L; Tan W
    Aging (Albany NY); 2021 Aug; 13(16):20468-20480. PubMed ID: 34424218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
    Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
    JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.